In the last week, the United States market has stayed flat, but it is up 20% over the past year, with earnings expected to grow by 18% per annum over the next few years. Investing in penny stocks—though often considered a niche area—can still present growth opportunities, especially when these stocks are supported by strong financial health. Here, we explore several intriguing penny stocks that stand out for their financial strength and potential for long-term growth.

Here's a peek at a few of the choices from the screener.

Sera Prognostics (SERA)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Sera Prognostics, Inc. is a women's health company focused on discovering, developing, and commercializing blood-based biomarker tests and predictive analytic products in the United States, with a market cap of $78.32 million.

Operations: The company's revenue is primarily derived from the development and commercialization of its medical diagnostic products, totaling $0.057 million.

Market Cap: $78.32M

Sera Prognostics, with a market cap of US$78.32 million, is pre-revenue, generating only US$57K in revenue. Despite its unprofitability and forecasted earnings decline over the next three years, it benefits from a strong balance sheet with short-term assets exceeding liabilities and no debt. Recent strategic moves include joining the Russell Microcap and 3000E Value Indexes and participating in a significant ARPA-H funded research program to develop innovative diagnostic tests for maternal health. The appointment of experienced executive Mark Capone as director could enhance leadership capabilities amid ongoing efforts to advance its diagnostic technologies.

Tilly's (TLYS)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Tilly's, Inc. is a specialty retailer in the United States offering casual apparel, footwear, accessories, and hardgoods for young men and women as well as boys and girls, with a market cap of approximately $120.12 million.

Operations: The company's revenue is primarily derived from its retail segment focused on apparel, generating $570.69 million.

Market Cap: $120.12M

Tilly's, Inc., with a market cap of US$120.12 million, is currently unprofitable and faces challenges such as a negative return on equity and increased losses over the past five years. Despite having no debt and short-term assets exceeding liabilities, its management team lacks experience with an average tenure of 1.7 years. The company recently reported improved quarterly sales of US$124.72 million but still incurred a net loss of US$7.95 million. Strategic moves include joining the Russell Microcap Growth and 3000E Growth Indexes and filing a shelf registration for potential capital raising through an ESOP-related offering.

Vivos (RDGL)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Vivos Inc. is a radiation oncology medical device company focused on developing yttrium-90-based precision radionuclide therapy devices for treating non-resectable tumors in the United States, with a market cap of $28.27 million.

Operations: The company's revenue is primarily generated from its Diagnostic Kits and Equipment segment, amounting to $0.08 million.

Market Cap: $28.27M

Vivos Inc., with a market cap of US$28.27 million, is a pre-revenue company focused on developing yttrium-90-based cancer therapies. Recent FDA approval for its Feasibility IDE application allows it to begin human trials for RadioGel at Mayo Clinic, marking progress in its regulatory pathway. Despite generating minimal revenue from diagnostic kits, Vivos maintains a stable cash runway and has no debt. Its stock exhibits high volatility, but short-term assets exceed liabilities. The company's strategy includes expanding IsoPet's veterinary use and pursuing international opportunities for its technologies while managing increased losses over the past five years.

Key Takeaways

• Click here to access our complete index of 321 US Penny Stocks.
• Searching for a Fresh Perspective? Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.